Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine

Table 1 Treatment-Emergent Adverse Events (TEAEs) Reported in ≥2% of Participants (Safety Population, N = 335

SOC Preferred Term	All Adverse Events n (%) of Participants
Application site erythema^a	316 (94.3)
Application site swelling^a	296 (88.4)
Application site haemorrhage^a	225 (67.2)
Application site bruise^a	194 (57.9)
Application site pain^a	81 (24.2)
Application site discolouration^a	53 (15.8)
Application site pruritus^a	52 (15.5)
Application site oedema^a	8 (2.4)
Upper respiratory tract infection	28 (8.4)
Sinusitis	13 (3.9)
Nausea	9 (2.7)
Viral upper respiratory tract infection	7 (2.1)

A participant who experienced multiple events within a SOC was counted only once for that SOC
Adverse events were coded with MedDRA v 20.0
SOC System Organ Class
^aAdverse Event was considered possibly or probably drug-related

ISSN: 1129-2377